Artemis Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Artemis Therapeutics generated cash of -$390,000, which is less than the previous year. Cash used in financing activities reached the amount of $0 last year. Net change in cash is therefore -$416,000.
Cash Flow
| 2013 | -246K | -16K | 0 |
|---|---|---|---|
| 2014 | 465K | -186K | 0 |
| 2015 | -190K | 205K | 0 |
| 2016 | -276K | 0 | 1.18M |
| 2017 | -926K | 0 | 544K |
| 2018 | -518K | 0 | 0 |
| 2019 | -108K | 0 | 103K |
| 2020 | -1K | 0 | 0 |
| 2021 | -73K | 0 | 73K |
| 2022 | -390K | -26K | 0 |
ATMS Cash Flow Statement (2013 – 2022)
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 471K | 1K | 2K | 7K | 525K | 907K | 628K | 613K | 334K | 596K |
Operating activities | ||||||||||
Net income | -1.35M | -167K | -121K | -121K | -513K | -1.14M | -264K | -139K | 362K | -298K |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 16K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4K | 19K |
Stock-based compensation expense | 247K | 16K | 14K | 17K | 0 | 0 | 0 | 0 | 0 | -12K |
| Deferred income tax benefit | 247K | 16K | 14K | 17K | 0 | 0 | 0 | 0 | 0 | -12K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | -16K | 4K | 10K | 0 | 38K | 7K | 0 | 0 | 26K | 95K |
Inventories | 27K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 229K | 93K |
Accounts payable | 690K | 0 | 0 | 0 | 0 | 0 | 0 | -5K | -140K | 61K |
Cash generated by operating activities | -390K | -73K | -1K | -108K | -518K | -926K | -276K | -190K | 465K | -246K |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -26K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -26K | 0 | 0 | 0 | 0 | 0 | 0 | 205K | -186K | -16K |
Financing activities | ||||||||||
Common Stock Issued | 0 | 0 | 0 | 0 | 0 | 544K | 0 | 0 | 0 | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 608K | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 0 | 73K | 0 | 103K | 0 | 544K | 1.18M | 0 | 0 | 0 |
Net Change In Cash | -416K | 0 | -1K | -5K | -518K | -382K | 907K | 15K | 279K | -262K |
Cash at end of period | 55K | 1K | 1K | 2K | 7K | 525K | 1.53M | 628K | 613K | 334K |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |